CancerIntercept® Detect is a blood-based non-invasive test that can be used by physicians for the detection of circulating tumor DNA (ctDNA). Presence of increased levels of ctDNA and of the distinct mutations in the covered driver genes has been seen in many cancer types when disease is developing or is present. This test works by analyzing cell-free DNA (cfDNA). It detects the presence of specific genomic markers called circulating tumor DNA (ctDNA) in 9 cancer driver genes. CancerIntercept® Detect delivers results in just 2 to 3 weeks.
Liquid Biopsy Definition
Liquid biopsy is a molecular diagnostics technique that uses bodily fluids, such as blood, to analyze tumor DNA that is present in patients found to have cancer.
Both normal and tumor cells release small DNA fragments into the bloodstream (cell-free DNA or cfDNA). Analysis of circulating tumor DNA may give valuable information about the underlying genomic make-up of a patient’s tumor.
Appropriate Candidates for Testing
CancerIntercept® Detect is available for patients that are at high risk to develop cancer in their lifetime.
There are a number of conditions that may put on individual at an increased risk for the development of cancer, including, but not limited to:
Our complete clinical history questionnaire, which details the potential risk factors for cancer, can be found here.
In order for an individual to be eligible to order CancerIntercept® Detect, he or she must be at an increased risk, to be acknowledged by their physician. Eligibility will be reviewed by Pathway Genomics clinical staff. CancerIntercept® is not for asymptomatic individuals that have no known risk factors.
How Does Testing Work?
Many types of cancers can be difficult to diagnose at an early stage and give poor outcome if not identified at an early stage. Using cutting-edge technology, CancerIntercept® Detect offers physicians a new tool to look for ctDNA in high-risk patients to potentially aid in early diagnosis.
CancerIntercept® Detect is a non-invasive testing method that utilizes blood plasma to test for circulating tumor DNA. Both tumor and non-tumor cells release small DNA fragments into the bloodstream. Presence of increased levels of ctDNA and of the distinct mutations in the covered driver genes has been seen in many cancer types when disease is developing or is present. This test works by analyzing cell-free DNA (cfDNA). It detects the presence of specific genomic markers called circulating tumor DNA (ctDNA) in 9 cancer driver genes.
Testing is by physician order. After all paperwork is submitted to Pathway, and patient eligibility is confirmed by our clinical staff, a sample collection kit will be sent to the patient’s primary care physician or to the phlebotomist for the blood draw. All samples are processed in our CLIA/CAP approved laboratory in San Diego.
This test is not diagnostic. A positive result with CancerIntercept® Detect requires additional confirmatory testing to rule in, or rule out, the presence of a cancer diagnosis.
A negative result means that none of the 96 genomic markers included in this test were identified in the blood sample provided. This result does not rule out the presence of a current or future cancer, nor does it change the patient’s future cancer risk.
Results are released to the patient’s physician and the patient on request. A positive result is released first to the patient’s primary care physician and then to the patient, so that results can be discussed.
Negative test results are released to the patient’s physician and the patient. Pathway’s oncologist is available to consult with the patient’s physician about the test results.
What Exactly Is Being Tested?
An individual’s blood plasma is analyzed for the presence of 96 specific genomic markers that are potentially found in several specific tumor types. Please click below for a full list of the included markers.